pharma · Waldenstrom Macroglobulinemia · Non Small Cell Lung Cancer · CLRB
Cellectar Biosciences
Cellectar Biosciences patent portfolio — 7 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- 100 Campus Dr, 207, Florham Park, New Jersey 07932, US
- Employees
- 21
- Programs
- 17
- Drugs
- 7
- Patents
- 7
Cellectar Biosciences patents
7 pharmaceutical patents indexed for Cellectar Biosciences. 0 expire within 24 months.
Cellectar Biosciences has 7 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 11439709
Phospholipid ether analogs as cancer-targeting drug vehicles
granted -
US 9925269
Phospholipid ether analogs as cancer-targeting drug vehicles
granted -
US 9616140
Fluorescent phospholipid ether compounds, compositions, and methods of use
granted -
US 9579406
Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
granted -
US 9550002
Phospholipid analogs as diapeutic agents and methods thereof
granted -
US 9480754
Phospholipid ether analogs as cancer-targeting drug vehicles
granted -
US 9345718
Phospholipid ether analogs as cancer-targeting drug vehicles
granted
Frequently asked questions
How many patents does Cellectar Biosciences have?
7 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Cellectar Biosciences patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.